Skip to main content

New Indications & Dosage Forms for Existing Drugs

Drugs that have gained FDA approval for the treatment of additional diseases/conditions or new dosage forms/regimens.

Gamifant (emapalumab-lzsg) Injection

New Indication Approved: June 28, 2025
Date of Original Approval: November 20, 2018

Gamifant (emapalumab-lzsg) is an interferon gamma (IFNγ) blocking antibody for the treatment of primary hemophagocytic lymphohistiocytosis and macrophage activation syndrome in Still’s disease.

Gammagard Liquid (immune globulin infusion (human)) Solution

New Formulation Approved: June 27, 2025
Date of Original Approval: April 27, 2005

Gammagard Liquid (immune globulin infusion (human)) is an immune globulin therapy for use in the treatment of primary humoral immunodeficiency, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Breyanzi (lisocabtagene maraleucel) Suspension for Intravenous Infusion

Labeling Revision Approved: June 26, 2025
Date of Original Approval: February 5, 2021

Breyanzi (lisocabtagene maraleucel) is a CD-19 directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma.

Datroway (datopotamab deruxtecan-dlnk) Lyophilized Powder for Injection

New Indication Approved: June 23, 2025
Date of Original Approval: January 17, 2025

Datroway (datopotamab deruxtecan-dlnk) is a TROP2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Vizamyl (flutemetamol F 18) Injection

Labeling Revision Approved: June 23, 2025
Date of Original Approval: October 25, 2013

Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease and other cognitive disorders.

Benlysta (belimumab) Injection

New Dosage Regimen: June 20, 2025
Date of Original Approval: March 10, 2011

Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor for the treatment of active systemic lupus erythematosus (SLE) and active lupus nephritis.

Dupixent (dupilumab) Injection

New Indication Approved: June 18, 2025
Date of Original Approval: March 28, 2017

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist used for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria, and bullous pemphigoid.

Monjuvi (tafasitamab-cxix) for Injection

New Indication Approved: June 18, 2025
Date of Original Approval: July 31, 2020

Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody used in the treatment of diffuse large B-cell lymphoma and follicular lymphoma.

Endari (L-glutamine) Oral Powder

Labeling Revision Approved: June 18, 2025
Date of Original Approval: July 7, 2017

Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia.

mRESVIA (respiratory syncytial virus vaccine, mRNA) Injection

Patient Population Altered: June 12, 2025
Date of Original Approval: May 31, 2024

mRESVIA is a modified RNA vaccine for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV).

Keytruda (pembrolizumab) for Injection

New Indication Approved: June 12, 2025
Date of Original Approval: September 4, 2014

Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody used to treat multiple types of cancer.

Steqeyma (ustekinumab-stba) Injection

New Dosage Form Approved: June 12, 2025
Date of Original Approval: December 17, 2024

Steqeyma (ustekinumab-stba) is a human interleukin-12 and -23 antagonist interchangeable biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Mavyret (glecaprevir and pibrentasvir) Tablets and Oral Pellets

New Indication Approved: June 10, 2025
Date of Original Approval: August 3, 2017

Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, used for the treatment of all major genotypes (GT1-6) of chronic hepatitis C.

Brukinsa (zanubrutinib) Capsules and Tablets

New Dosage Form Approved: June 10, 2025
Date of Original Approval: November 14, 2019

Brukinsa (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor used for the treatment of mantle cell lymphoma, Waldenström’s macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and follicular lymphoma.

Nubeqa (darolutamide) Tablets

New Indication Approved: June 3, 2025
Date of Original Approval: July 30, 2019

Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) used in the treatment of prostate cancer.

Xenoview (xenon Xe 129 hyperpolarized) for Oral Inhalation

Patient Population Altered: May 30, 2025
Date of Original Approval: December 23, 2022

Xenoview (xenon Xe 129 hyperpolarized) is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.

Nucala (mepolizumab) Injection

New Indication Approved: May 22, 2025
Date of Original Approval: November 4, 2015

Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) used for the treatment of with severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.

Zoryve (roflumilast) Cream and Foam

New Indication Approved: May 22, 2025
Date of Original Approval: July 29, 2022

Zoryve (roflumilast) is a topical phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of plaque psoriasis (0.3% cream, 0.3% foam), atopic dermatitis (0.15% cream) and seborrheic dermatitis (0.3% foam).

Susvimo (ranibizumab) Injection for Intravitreal Use via Ocular Implant

New Indication Approved: May 21, 2025
Date of Original Approval: October 25, 2021

Susvimo (ranibizumab) is a vascular endothelial growth factor (VEGF) inhibitor used for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Yuflyma (adalimumab-aaty) Injection

Labeling Revision Approved: May 21, 2025
Date of Original Approval: May 23, 2023

Yuflyma (adalimumab-aaty) is a tumor necrosis factor (TNF) blocker biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Hadlima (adalimumab-bwwd) Injection

Labeling Revision Approved: May 21, 2025
Date of Original Approval: July 23, 2019

Hadlima (adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker interchangeable biosimilar to Humira indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Jivi (antihemophilic factor [recombinant] PEGylated-aucl) Injection

Patient Population Altered: May 19, 2025
Date of Original Approval: August 30, 2018

Jivi (antihemophilic factor (recombinant), PEGylated-aucl) is a recombinant DNA-derived, factor VIII concentrate used to treat and control bleeding in patients with hemophilia A.

Zynyz (retifanlimab-dlwr) Injection

New Indication Approved: May 15, 2025
Date of Original Approval: March 22, 2023

Zynyz (retifanlimab-dlwr) is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of advanced anal cancer and Merkel cell carcinoma.

Welireg (belzutifan) Tablets

New Indication Approved: May 14, 2025
Date of Original Approval: August 13, 2021

Welireg (belzutifan) is a selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α) for the treatment of von Hippel-Lindau (VHL) disease, advanced renal cell carcinoma, and pheochromocytoma or paraganglioma (PPGL).

Selarsdi (ustekinumab-aekn) Injection

Labeling Revision Approved: April 30, 2025
Date of Original Approval: April 16, 2024

Selarsdi (ustekinumab-aekn) is a human interleukin-12 and -23 antagonist interchangeable biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Otulfi (ustekinumab-aauz) Injection

Labeling Revision Approved: April 30, 2025
Date of Original Approval: September 27, 2024

Otulfi (ustekinumab-aauz) is a human interleukin-12 and -23 antagonist interchangeable biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Rinvoq (upadacitinib) Extended-Release Tablets

New Indication Approved: April 28, 2025
Date of Original Approval: August 16, 2019

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis.

Camzyos (mavacamten) Capsules

Labeling Revision Approved: April 17, 2025
Date of Original Approval: April 28, 2022

Camzyos (mavacamten) is a first-in-class cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Dupixent (dupilumab) Injection

New Indication Approved: April 17, 2025
Date of Original Approval: March 28, 2017

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist used for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria, and bullous pemphigoid.

Valtoco (diazepam) Nasal Spray

Patient Population Altered: April 16, 2025
Date of Original Approval: January 10, 2020

Valtoco (diazepam) is an immediate-use benzodiazepine nasal spray for the short-term treatment of seizure clusters in patients with epilepsy.

Isturisa (osilodrostat) Tablets

New Indication Approved: April 15, 2025
Date of Original Approval: March 6, 2020

Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.

Livmarli (maralixibat) Oral Solution and Tablets

New Formulation Approved: April 14, 2025
Date of Original Approval: September 29, 2021

Livmarli (maralixibat) is an ileal bile acid transporter (IBAT) inhibitor used for the treatment of cholestatic pruritus in patients with Alagille syndrome or progressive familial intrahepatic cholestasis.

Opdivo (nivolumab) Injection

New Indication Approved: April 11, 2025
Date of Original Approval: December 22, 2014

Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer.

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection

New Dosage Form Approved: April 10, 2025
Date of Original Approval: June 20, 2023

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a neonatal Fc receptor blocker and endoglycosidase combination used for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Vitrakvi (larotrectinib) Capsules and Oral Solution

Labeling Revision Approved: April 9, 2025
Date of Original Approval: November 26, 2018

Vitrakvi (larotrectinib) is a tropomyosin receptor kinase inhibitor used for the treatment of solid tumors.

Opdivo (nivolumab) Injection

New Indication Approved: April 8, 2025
Date of Original Approval: December 22, 2014

Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer.

Yuflyma (adalimumab-aaty) Injection

Labeling Revision Approved: April 7, 2025
Date of Original Approval: May 23, 2023

Yuflyma (adalimumab-aaty) is a tumor necrosis factor (TNF) blocker biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Uplizna (inebilizumab-cdon) Injection

New Indication Approved: April 3, 2025
Date of Original Approval: June 11, 2020

Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody used for the treatment of neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease.

Tryvio (aprocitentan) Tablets

Labeling Revision Approved: April 2, 2025
Date of Original Approval: March 19, 2024

Tryvio (aprocitentan) is an endothelin receptor antagonist (ERA) for the combination treatment of hypertension that is not adequately controlled with other drugs.

Jynneos (smallpox and mpox vaccine) Injection

New Formulation Approved: March 31, 2025
Date of Original Approval: September 24, 2019

Jynneos (smallpox and mpox vaccine, live, non-replicating) is a vaccine for the prevention of smallpox and mpox disease.

Pluvicto (lutetium lu 177 vipivotide tetraxetan) Injection

New Indication Approved: March 28, 2025
Date of Original Approval: March 23, 2022

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent for use in the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Imfinzi (durvalumab) Injection

New Indication Approved: March 28, 2025
Date of Original Approval: May 1, 2017

Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used for the treatment of non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, endometrial cancer, and bladder cancer.

Cabometyx (cabozantinib) Tablets

New Indication Approved: March 26, 2025
Date of Original Approval: April 25, 2016

Cabometyx (cabozantinib) is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors.

Egrifta WR (tesamorelin) Injection

New Formulation Approved: March 25, 2025
Date of Original Approval: November 10, 2010

Egrifta WR (tesamorelin) is a synthetic analogue of growth hormone releasing factor (GRF) for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

Amvuttra (vutrisiran) Injection

New Indication Approved: March 20, 2025
Date of Original Approval: June 13, 2022

Amvuttra (vutrisiran) is an RNAi therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis.

Fabhalta (iptacopan) Capsules

New Indication Approved: March 20, 2025
Date of Original Approval: December 5, 2023

Fabhalta (iptacopan) is a complement factor B inhibitor used for the treatment of paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

Tremfya (guselkumab) Injection

New Indication Approved: March 20, 2025
Date of Original Approval: July 13, 2017

Tremfya (guselkumab) is an interleukin-23 blocker for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Keytruda (pembrolizumab) for Injection

Labeling Revision Approved: March 19, 2025
Date of Original Approval: September 4, 2014

Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody used to treat multiple types of cancer.

Gvoke (glucagon) Injection

New Indication Approved: March 14, 2025
Date of Original Approval: September 10, 2019

Gvoke (glucagon injection) is a ready-to-use, room-temperature stable, liquid glucagon for the treatment of hypoglycemia. Gvoke VialDx (glucagon injection) is used as a diagnostic aid.

Iluvien (fluocinolone acetonide) Intravitreal Implant

New Indication Approved: March 12, 2025
Date of Original Approval: September 26, 2014

Iluvien (fluocinolone acetonide) is a corticosteroid implant for the treatment of diabetic macular edema and posterior uveitis.

See also: New Drug Approvals, New Drug Applications, Recent Additions to Drugs.com

New indications and dosage forms archive